KR20160008121A - Composition containing amorpha fruticosa extract - Google Patents
Composition containing amorpha fruticosa extract Download PDFInfo
- Publication number
- KR20160008121A KR20160008121A KR1020150165755A KR20150165755A KR20160008121A KR 20160008121 A KR20160008121 A KR 20160008121A KR 1020150165755 A KR1020150165755 A KR 1020150165755A KR 20150165755 A KR20150165755 A KR 20150165755A KR 20160008121 A KR20160008121 A KR 20160008121A
- Authority
- KR
- South Korea
- Prior art keywords
- fraction
- composition
- extract
- skin
- weasel
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 98
- 239000000284 extract Substances 0.000 title claims abstract description 62
- 240000002066 Amorpha fruticosa Species 0.000 title abstract description 4
- 235000004047 Amorpha fruticosa Nutrition 0.000 title abstract description 4
- 230000000694 effects Effects 0.000 claims description 43
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 24
- 230000015572 biosynthetic process Effects 0.000 claims description 19
- 230000014509 gene expression Effects 0.000 claims description 17
- 239000004480 active ingredient Substances 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 230000003020 moisturizing effect Effects 0.000 claims description 10
- 108010063290 Aquaporins Proteins 0.000 claims description 9
- 102000010637 Aquaporins Human genes 0.000 claims description 8
- 238000003786 synthesis reaction Methods 0.000 claims description 8
- 239000002537 cosmetic Substances 0.000 claims description 6
- 239000000401 methanolic extract Substances 0.000 claims description 6
- 235000013402 health food Nutrition 0.000 claims description 5
- 239000002034 butanolic fraction Substances 0.000 claims description 4
- 239000002038 ethyl acetate fraction Substances 0.000 claims description 4
- 239000002044 hexane fraction Substances 0.000 claims description 4
- 241000254171 Curculionidae Species 0.000 claims 2
- 239000000469 ethanolic extract Substances 0.000 claims 2
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims 2
- 229950004354 phosphorylcholine Drugs 0.000 claims 2
- 235000021028 berry Nutrition 0.000 claims 1
- 238000000855 fermentation Methods 0.000 claims 1
- 230000004151 fermentation Effects 0.000 claims 1
- 230000003712 anti-aging effect Effects 0.000 abstract description 8
- 241001504654 Mustela nivalis Species 0.000 description 54
- 210000003491 skin Anatomy 0.000 description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 238000009472 formulation Methods 0.000 description 16
- 238000000605 extraction Methods 0.000 description 14
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 13
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 13
- 239000004615 ingredient Substances 0.000 description 12
- 108010035532 Collagen Proteins 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 11
- 108010067372 Pancreatic elastase Proteins 0.000 description 11
- 102000016387 Pancreatic elastase Human genes 0.000 description 11
- 229920001436 collagen Polymers 0.000 description 11
- 230000037303 wrinkles Effects 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 9
- 108010026132 Gelatinases Proteins 0.000 description 9
- 102000013382 Gelatinases Human genes 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 230000032683 aging Effects 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 210000002510 keratinocyte Anatomy 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 7
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 7
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 7
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 7
- 102000005741 Metalloproteases Human genes 0.000 description 7
- 108010006035 Metalloproteases Proteins 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 102000029816 Collagenase Human genes 0.000 description 6
- 108060005980 Collagenase Proteins 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 6
- 229960002424 collagenase Drugs 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 108090000991 Aquaporin 3 Proteins 0.000 description 5
- 108010014258 Elastin Proteins 0.000 description 5
- 102100028314 Filaggrin Human genes 0.000 description 5
- 101710088660 Filaggrin Proteins 0.000 description 5
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 5
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000009759 skin aging Effects 0.000 description 5
- 230000008591 skin barrier function Effects 0.000 description 5
- 230000037394 skin elasticity Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- 102000004363 Aquaporin 3 Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000016942 Elastin Human genes 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 229920002549 elastin Polymers 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100033174 Neutrophil elastase Human genes 0.000 description 3
- 235000002789 Panax ginseng Nutrition 0.000 description 3
- 108010050808 Procollagen Proteins 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 102000007236 involucrin Human genes 0.000 description 3
- 108010033564 involucrin Proteins 0.000 description 3
- 150000002632 lipids Chemical group 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- ACFGRWJEQJVZTM-LEJBHHMKSA-L Magnesium L-ascorbic acid-2-phosphate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1O ACFGRWJEQJVZTM-LEJBHHMKSA-L 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102100033142 Transcription factor 20 Human genes 0.000 description 2
- 101710119730 Transcription factor 20 Proteins 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- -1 blockers Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 230000037384 skin absorption Effects 0.000 description 2
- 231100000274 skin absorption Toxicity 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- BWSWZBCSFZAYOB-CABCVRRESA-N (2s,4r)-1-dodecanoyl-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCC(=O)N1C[C@H](O)C[C@H]1C(O)=O BWSWZBCSFZAYOB-CABCVRRESA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 102000015279 Basigin Human genes 0.000 description 1
- 108010064528 Basigin Proteins 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- 241000218631 Coniferophyta Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102100033167 Elastin Human genes 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000627854 Homo sapiens Matrix metalloproteinase-26 Proteins 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 240000005783 Lathyrus sativus Species 0.000 description 1
- 235000010671 Lathyrus sativus Nutrition 0.000 description 1
- 108700010340 Leishmanolysins Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102100030417 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 1
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 1
- 108090000609 Matrix metalloproteinase-20 Proteins 0.000 description 1
- 102000004159 Matrix metalloproteinase-20 Human genes 0.000 description 1
- 102100024129 Matrix metalloproteinase-24 Human genes 0.000 description 1
- 108050005214 Matrix metalloproteinase-24 Proteins 0.000 description 1
- 102100024131 Matrix metalloproteinase-25 Human genes 0.000 description 1
- 102100024128 Matrix metalloproteinase-26 Human genes 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 102000036436 Metzincins Human genes 0.000 description 1
- 101150101095 Mmp12 gene Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 244000086363 Pterocarpus indicus Species 0.000 description 1
- 235000009984 Pterocarpus indicus Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 102100028848 Stromelysin-2 Human genes 0.000 description 1
- 101710108792 Stromelysin-2 Proteins 0.000 description 1
- 102100028847 Stromelysin-3 Human genes 0.000 description 1
- 108050005271 Stromelysin-3 Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 102000036861 Zinc-dependent endopeptidases Human genes 0.000 description 1
- 108091006982 Zinc-dependent endopeptidases Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008687 biosynthesis inhibition Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000036569 collagen breakdown Effects 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 108090000440 matrix metalloproteinase 25 Proteins 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000019449 other food additives Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 238000007805 zymography Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A23L1/3002—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 족제비싸리 추출물 또는 그의 분획물을 포함하는 항노화용 또는 보습용 조성물에 관한 것이다. The present invention relates to an anti-aging or moisturizing composition comprising a weasel extract or a fraction thereof.
피부노화 과정은 일반적으로 내인성 노화(intrinsic aging)와 광노화(photoaging)에 의해 일어난다(Gilchrest, 1989; Ma etal.,2001;Jenkins,2002). 내인성 노화는 시간이 지남에 따라 신진대사를 조절하는 각종 호르몬의 분비가 감소하고, 면역 세포의 기능과 세포들의 활성이 저하되어 생체에 필요한 면역 단백질 및 생체 구성 단백질들의 생합성이 줄어들게 되어 일어나며, 외인성 노화는 오존층 파괴로 인하여 태양 광선 중 지표에 도달하는 자외선의 함량이 증가하게 되고 환경 오염이 더욱 심화됨에 따라, 피부의 두께가 감소하고, 주름이 증가되고, 탄력이 감소될 뿐 아니라, 기미, 주근깨 및 검버섯 또한 증가하는 등 여러 가지 변화를 일으키게 된다. 피부는 표피, 표피진피경계부, 진피, 피하지방층의 순서로 구성되며, 표피는 외부로부터 순서대로 각질층, 과립층, 유극층, 기저층으로 구분되며, 각질층의 세포들은 벽돌과 같은 역할을 하고 각질세포 사이의 세포간 지질들은 모르타르와 같은 역할로 작용하여 피부 장벽을 구성한다(J. Invest. Dermatol. 80 (Suppl.), 44-49. 1983). 또한, 건강한 사람의 각질세포에는 고농도의 자연보습인자(Natural Moisturing Factor, NMF)가 존재하여 피부의 수분 보유를 돕는데, 예를 들면 아미노산과 같은 물질은 수용성이기 때문에 효과적으로 수분과 결합하여 피부에서 수분이 건조되는 것을 억제한다(J. Invest. Dermatol. 54, 24-31, 1970). 최근에 알려진 Aquaporin 단백질은 현재까지 13종류가 알려져 있으며, 글리세롤, 우레아 등의 small neutral solutes 및 물을 전달하는 단백질로서 피부장벽기능, 각질층 수분 공급, 상처치료 등에 중요한 역할을 하는 것으로 알려져 있다. 특히 Aquaporin 3 단백질이 피부에서 주요 기능들을 나타내는 것으로 알려져 있다 (Exp Dermatol. 20, 595-599, 2011). The skin aging process is generally caused by intrinsic aging and photoaging (Gilchrest, 1989; Ma etal., 2001; Jenkins, 2002). Endogenous aging occurs when the secretion of various hormones that regulate metabolism decreases over time, the function of immune cells and the activity of cells decrease, resulting in a decrease in the biosynthesis of immune proteins and biological components necessary for the living body, and exogenous aging. As the content of ultraviolet rays reaching the surface of the sun's rays increases due to the destruction of the ozone layer and environmental pollution becomes more intense, the skin thickness decreases, wrinkles increase, elasticity decreases, as well as spots, freckles and Age spots also increase, causing various changes. The skin is composed of the epidermis, the epidermal dermal border, the dermis, and the subcutaneous fat layer in order, and the epidermis is divided into the stratum corneum, granule layer, play layer, and basal layer in order from the outside. Intercellular lipids form the skin barrier by acting in the same role as mortar (J. Invest. Dermatol. 80 (Suppl.), 44-49. 1983). In addition, a high concentration of natural moisturing factor (NMF) is present in the keratinocytes of a healthy person to help retain moisture in the skin.For example, substances such as amino acids are water-soluble, so they effectively bind to moisture and allow moisture from the skin. It inhibits drying (J. Invest. Dermatol. 54, 24-31, 1970). Recently, 13 types of Aquaporin proteins are known, and as a protein that transfers water and small neutral solutes such as glycerol and urea, it is known to play an important role in skin barrier function, stratum corneum hydration, and wound healing. In particular, Aquaporin 3 protein is known to exhibit major functions in the skin (Exp Dermatol. 20, 595-599, 2011).
그러나, 요즘과 같이 환경의 변화나 생활 패턴의 변화에 따른 냉/난방의 인위적인 온도 조절, 사회 생활에서 발생되는 각종 스트레스와 환경 오염으로 인한 피부 스트레스, 화장 습관에 따른 잦은 세안 및 연령 증가에 따른 자연적인 피부 노화 등의 여러 가지 원인으로 인하여 각질층의 수분이 감소하여 피부가 건조해지고 표면이 거칠게 되며 피부가 푸석거리고 촉촉함을 잃어 생기가 없어 보이는 등의 현상이 발생하기 때문에 피부 보습제의 필요가 증가하고 있다. 또한 외부로부터 받는 과도한 물리적, 화학적 자극, 자외선, 스트레스 및 영양결핍 등은 피부의 정상기능을 저하시키고 탄력손실, 각질화, 주름생성 등의 피부노화현상을 촉진시키게 되는데, 특히 자외선에 의해 표피 진피 경계부는 심하게 손상을 받는다. However, as in these days, artificial temperature control of cooling/heating according to changes in environment or life pattern, various stresses occurring in social life and skin stress due to environmental pollution, frequent washing according to makeup habits, and nature according to age increase. The need for skin moisturizers is increasing because moisture in the stratum corneum decreases due to various causes such as skin aging, which causes the skin to become dry, the surface becomes rough, and the skin becomes crumbly and looks dull due to loss of moisture. . In addition, excessive physical and chemical irritation, ultraviolet rays, stress, and nutritional deficiencies from the outside reduce the normal function of the skin and promote skin aging phenomena such as loss of elasticity, keratinization, and wrinkle formation. Severely damaged.
진피의 세포외 기질은 주로 콜라겐(콜라겐), 프로테오글리칸(proteoglycan) 및 당단백질 등의 구조단백질로 되어 있으며, 시기적절한 분해는 조직의 흡수와 재형성에 필수적인 현상이다. 세포외 기질의 분해는 주로 매트릭스 메탈로프로테이나제 (Matrix Metalloproteinases, MMPs)가 담당하고 있다. MMP는 zinc-dependent endopeptidase이며 1962년 올챙이 변태시 꼬리를 분해시키는 효소로 처음 발견되었으며 (Proc Natl Acad Sci USA 48 (6): 1014-22. 1962), 사람에서는 1968년에 보고되었으며 (Biochim Biophys Acta 151 (3): 637-45. 1968), 내인성 저해제로 TIMP (Tissue Inhibitor of Matrix Metalloproteinases)가 있다. MMP는 분해하는 기질 특이성에 따라서 collagenase (MMP-1, MMP-8, MMP-13), gelatinase (MMP-2, MMP-9), stromelysins (MMP-3, MMP-10, MMP-11), matrilysin (MMP-6, MMP-26), enamelysin (MMP-20), metalloelastase (MMP-12), membrane-type MMPs (MMP-14 ~ 17, MMP-24, MMP-25) 등이 있으며, 강력한 전사유도제로는 종양괴사인자(Tumor Necrosis Factor, TNF), BSG (Extracellular metrix metalloproteinase inducer, EMMPRIN), TCF20 (Transcription Factor 20)이 있다. 자외선 및 내외부인자에 의해 이러한 MMP의 발현 및 활성이 부적절하게 조절되면 피부는 심각한 손상을 받게되고 피부노화현상이 촉진되게 되므로, 피부노화 예방 및 개선의 주요한 타겟으로 주목받고 있다.The extracellular matrix of the dermis is mainly composed of structural proteins such as collagen (collagen), proteoglycan and glycoprotein, and timely decomposition is an essential phenomenon for tissue absorption and remodeling. The degradation of the extracellular matrix is mainly handled by Matrix Metalloproteinases (MMPs). MMP, a zinc-dependent endopeptidase, was first discovered in 1962 as an enzyme that degrades the tail during tadpole metamorphosis (Proc Natl Acad Sci USA 48 (6): 1014-22. 1962), and was reported in 1968 in humans (Biochim Biophys Acta). 151 (3): 637-45. 1968), as an endogenous inhibitor, is TIMP (Tissue Inhibitor of Matrix Metalloproteinases). MMP depends on the specificity of the substrate to degrade, collagenase (MMP-1, MMP-8, MMP-13), gelatinase (MMP-2, MMP-9), stromelysins (MMP-3, MMP-10, MMP-11), and matrilysin. (MMP-6, MMP-26), enamelysin (MMP-20), metalloelastase (MMP-12), membrane-type MMPs (MMP-14 ~ 17, MMP-24, MMP-25), etc., and strong transcription induction Zeros include Tumor Necrosis Factor (TNF), BSG (Extracellular metrix metalloproteinase inducer, EMMPRIN), and TCF20 (Transcription Factor 20). When the expression and activity of such MMPs are improperly controlled by ultraviolet rays and internal and external factors, the skin is seriously damaged and the skin aging phenomenon is promoted, and thus, it is attracting attention as a major target for skin aging prevention and improvement.
본 발명의 목적은 천연 유래의 항노화 또는 보습용 조성물을 제공하는 것이다. It is an object of the present invention to provide a natural anti-aging or moisturizing composition.
상기 목적을 달성하기 위해 본 발명의 일 관점은 족제비싸리 추출물 또는 그의 분획물을 유효성분으로 포함하는 항노화용 조성물을 제공한다. In order to achieve the above object, one aspect of the present invention provides an anti-aging composition comprising an extract or a fraction thereof as an active ingredient.
본 발명의 일 관점은 또한 족제비싸리 추출물 또는 그의 분획물을 유효성분으로 포함하는 보습용 조성물을 제공한다. One aspect of the present invention also provides a moisturizing composition comprising a weasel extract or a fraction thereof as an active ingredient.
본 발명의 조성물은 족제비싸리 추출물을 유효성분으로 포함하여, 항노화 및 보습 등의 효과를 가진다. 본 발명의 조성물은 예컨대, 메탈로프로테아제, 젤라티네이즈 또는 엘라스타제의 생합성을 억제시키거나 이의 활성을 저하시킬 수 있어서 피부 주름 개선, 피부 주름 완화, 탄력 개선, 피부 주름 생성 예방 등에 의해 노화를 예방하거나 지연시킬 수 있다는 장점이 있다. 본 발명의 조성물은 또한 예컨대, 필라그린 또는 인볼루크린의 합성을 촉진시키거나 이들의 활성을 증진시킬 수 있어서, 피부 보습 효과를 가져올 수 있고, 피부 장벽을 강화시킬 수 있으며, 이에 따라 아토피, 건선 등의 예방, 치료 또는 개선용으로 사용 가능하다. 아울러 본 발명의 조성물은 자연으로부터 얻어진 천연물을 유효성분으로 포함하여 인체에 적용시 부작용이 적을 뿐 아니라, 장기간 사용으로 인한 내성이 없다는 장점이 있어서, 피부 안정성 측면에서도 우수하다. The composition of the present invention contains an extract of weasel bissari as an active ingredient, and has anti-aging and moisturizing effects. The composition of the present invention can inhibit the biosynthesis of metalloprotease, gelatinase, or elastase, or reduce its activity, thereby reducing aging by improving skin wrinkles, alleviating skin wrinkles, improving elasticity, preventing skin wrinkles, etc. The advantage is that it can be prevented or delayed. The composition of the present invention can also promote the synthesis of, for example, filaggrin or involucrine or enhance their activity, thereby bringing about a skin moisturizing effect and strengthening the skin barrier, and thus atopy, psoriasis It can be used for prevention, treatment or improvement of the back. In addition, the composition of the present invention contains a natural product obtained from nature as an active ingredient and has the advantage of not only having few side effects when applied to the human body, but also having no resistance due to long-term use, and is excellent in terms of skin stability.
도 1은 자외선을 조사한 세포에 족제비싸리 추출물 또는 이의 분획물을 처리하는 경우 콜라게나제 I (MMP-1) 발현에 미치는 효과와 콜라겐의 양 변화를 관찰한 것이다.
도 2는 TNF-α를 처리한 세포에 족제비싸리 추출물 또는 이의 분획물을 처리한 경우, 콜라게나제 I (MMP-1) 발현에 미치는 효과를 관찰한 것이다.
도 3은 자외선을 조사한 세포에 족제비싸리 추출물 또는 이의 분획물을 처리하는 경우 젤라티나제 (MMP-2, MMP-9) 생합성에 미치는 효과를 나타낸 것이다.
도 4는 자외선을 조사한 세포에 족제비싸리 추출물 또는 이의 분획물을 처리하는 경우 젤라티나제 (MMP-2, MMP-9) 활성에 미치는 효과를 나타낸 것이다.
도 5는 족제비싸리 추출물 또는 이의 분획물이 엘라스타제 활성에 미치는 효과를 나타낸 것이다.
도 6은 족제비싸리 추출물 또는 이의 분획물이 필라그린 및 인볼루크린으 생합성에 미치는 효과를 나타낸 것이다.
도 7은 족제비싸리 추출물 또는 이의 분획물이 아쿠아포린 유전자의 발현에 미치는 효과를 나타낸 것이다. 1 shows the effect on the expression of collagenase I (MMP-1) and the change in the amount of collagen when treating a weasel extract or a fraction thereof on cells irradiated with ultraviolet rays.
Figure 2 is a case where the weasel extract or a fraction thereof was treated with TNF-α-treated cells, the effect on the expression of collagenase I (MMP-1) was observed.
Figure 3 shows the effect on the biosynthesis of gelatinase (MMP-2, MMP-9) when treating the weasel extract or a fraction thereof on the cells irradiated with ultraviolet rays.
Figure 4 shows the effect on the activity of gelatinase (MMP-2, MMP-9) when treating a weasel extract or a fraction thereof on cells irradiated with ultraviolet rays.
Figure 5 shows the effect of the weasel extract or a fraction thereof on the elastase activity.
Figure 6 shows the effect of a weasel extract or a fraction thereof on the biosynthesis of pilagrin and involukrin.
Figure 7 shows the effect of the weasel extract or a fraction thereof on the expression of aquaporin gene.
본 발명은 일 관점에서 족제비싸리 추출물을 유효성분으로 포함하는, 항노화용 조성물에 관한 것이다. In one aspect, the present invention relates to a composition for anti-aging, comprising an extract of weasel as an active ingredient.
본 명세서에서 “족제비싸리(Amorpha fruticosa)”는 쌍떡잎식물 장미목 콩과의 낙엽관목으로, 쪽싸리 또는 왜싸리라고도 하며, 북아메리카가 원산지이다. 잎은 싸리나무와 같고 씨앗은 백태콩깍지와 비슷하다. 높이는 3m 내외이고, 나무가지에 털이 있으나 성장하면서 점점 없어진다. 잎은 어긋나고 1회 깃꼴겹잎이다. 작은 잎은 11~25개씩이고 달걀 모양 또는 타원형이며 가장자리가 밋밋하다. 꽃은 5~6월에 피고 자줏빛이 도는 하늘색이며 향기가 강하다. 열매는 9월에 결실하며 협과이다. 열매에는 1개의 종자가 들어 있으며 신장 모양이다.In this specification, "Weasel ( Amorpha fruticosa )” is a deciduous shrub of the dicotyledonous rosewood leguminous family, and is also called indigo or herbarium, and is native to North America. The leaves are like a birch tree, and the seeds are similar to the white pea pods. The height is around 3m, and there are hairs on the branches of the tree, but they gradually disappear as they grow. The leaves are alternate, and it is a single pinnate compound leaf. There are 11-25 small leaves each, egg-shaped or oval, and the edges are flat. Flowers bloom in May-June, purple, light blue, and strong scent. The fruit is fruiting in September and is a conifer. The fruit contains 1 seed and is shaped like a kidney.
본 명세서에서 사용되는 족제비싸리는 그 입수 방법에 제한이 없으며, 재배하여 사용하거나 시판되는 것을 구입하여 사용할 수도 있다. 아울러 본 명세서에서 사용되는 족제비싸리는 족제비싸리 초본의 지상부 또는 지하부의 일부 또는 전부를 사용할 수 있다. 본 발명의 일 실시예에서는 족제비싸리의 지상부 (잎, 잔가지, 줄기 등) 중 종자(열매)를 이용하였으나, 이에 제한되는 것은 아니다. There is no limitation on the acquisition method of the weasel used in the present specification, and may be cultivated and used, or commercially available ones may be purchased and used. In addition, some or all of the above-ground or subterranean parts of the weasel herbaceous herb used in the present specification may be used. In one embodiment of the present invention, seeds (fruits) of the above-ground parts (leaves, twigs, stems, etc.) of weasel are used, but the present invention is not limited thereto.
본 명세서에서 “유효성분”은 단독으로 목적하는 활성을 나타내거나 또는 그 자체 활성이 없는 담체와 함께 활성을 나타낼 수 있는 성분을 의미하는 것이다.In the present specification, “active ingredient” refers to an ingredient that exhibits a desired activity alone or can exhibit activity together with a carrier that does not have its own activity.
본 명세서에서 “항노화”란 당업계에 일반적으로 알려진 노화 과정을 늦추거나 막거나 또는 예방할 수 있는 효능을 말하는 것으로, 구체적으로 피부내 콜라게나제의 발현을 효과적으로 억제함으로써 피부 내의 콜라겐 분해를 감소시켜 피부 탄력을 증진시키고 주름을 개선시키는 등의 효능을 의미하거나, 메탈로프로테아제, 젤라티네이즈 또는 엘라스타제의 합성을 억제하거나 이들의 활성을 저해하여 일반적으로 알려진 노화 현상의 지연 또는 예방할 수 있는 효능을 의미할 수 있지만 이에 제한되는 것은 아니다. In the present specification, “anti-aging” refers to an effect that can slow, block, or prevent the aging process generally known in the art. Specifically, by effectively inhibiting the expression of collagenase in the skin, the degradation of collagen in the skin is reduced. Efficacy in improving skin elasticity and improving wrinkles, or inhibiting the synthesis of metalloprotease, gelatinase, or elastase, or inhibiting their activity, thereby delaying or preventing commonly known aging phenomena. It may mean, but is not limited thereto.
본 명세서에서 상기 족제비싸리 “추출물”은 당업계에 알려진 추출법이라면 제한 없이 사용하여 얻어질 수 있다. 구체적으로 상기 족제비싸리 추출물은 물, C1-C6 알콜, 및 이들이 조합으로 구성된 그룹에서 선택된 용매의 추출물을 포함하는 것이나, 이에 제한되는 것은 아니다. 본 발명의 족제비싸리 추출물은 예컨대 다음과 같이 얻어질 수 있으나 이에 제한되는 것은 아니다. 족제비싸리를 용매로 추출 시, 족제비싸리의 약 5 내지 15배 정도에 해당하는 용매를 가하여 추출할 수 있고, 구체적으로 약 10 배의 용매를 가하여 추출할 수 있으나, 이에 한정되는 것은 아니다. 상기 추출은 가열 추출, 냉침 추출, 환류냉각 추출, 또는 초음파 추출 등이 이용될 수 있으며, 당업자에게 자명한 추출법이라면 제한이 없다. 상기 추출은 실온에서 수행할 수도 있으나, 보다 효율적인 추출을 위해서는 가온 조건 하에서 수행할 수 있으며, 약 40 내지 100℃의 온도에서 추출할 수 있으나, 이에 한정되는 것은 아니다. 추출시간은 약 2 내지 4시간일 수 있으나 이에 한정되는 것은 아니며, 추출 용매 및 추출 온도 등의 조건에 따라 달라질 수 있다. 상기 추출은 활성성분을 보다 다량 수득하기 위해 1 회 이상 여러 번 추출할 수 있으며, 예컨대1 내지 5회 또는 3회 연속추출하여 합한 추출액을 이용할 수 있다.In the present specification, the weasel "extract" may be obtained using any extraction method known in the art without limitation. Specifically, the weasel extract includes, but is not limited to, an extract of a solvent selected from the group consisting of water, C1-C6 alcohol, and combinations thereof. The weasel extract of the present invention may be obtained, for example, as follows, but is not limited thereto. When extracting the weasel with a solvent, it may be extracted by adding a solvent corresponding to about 5 to 15 times that of the weasel, and specifically, it may be extracted by adding about 10 times more solvent, but is not limited thereto. Heat extraction, cold needle extraction, reflux cooling extraction, or ultrasonic extraction may be used for the extraction, and there is no limitation as long as the extraction method is obvious to those skilled in the art. The extraction may be performed at room temperature, but for more efficient extraction, it may be performed under a heated condition, and extraction may be performed at a temperature of about 40 to 100°C, but is not limited thereto. The extraction time may be about 2 to 4 hours, but is not limited thereto, and may vary depending on conditions such as an extraction solvent and extraction temperature. The extraction may be extracted once or more several times in order to obtain a larger amount of the active ingredient, for example, 1 to 5 times or 3 times continuous extraction and a combined extract may be used.
본 발명의 일 관점인 조성물에 있어서, 상기 족제비싸리 추출물은 족제비싸리의 메탄올 추출물일 수 있고, 족제비싸리 종자(열매)의 메탄올 추출물일 수 있다. In the composition of one aspect of the present invention, the weasel extract may be a methanol extract of weasel and may be a methanol extract of a weasel seed (fruit).
본 명세서에서 족제비싸리 “분획물”은 상기 언급한 바와 같이 당압계에 자명한 방법으로 얻어진 족제비싸리 추출물을 더욱 추출하여 얻어진 분획물을 의미한다. 상기 분획물을 얻기 위해서 당업계에 알려진 방법은 제한 없이 사용 가능하다. 구체적으로, 상기 분획물은 족제비싸리 추출물을 극성이 낮은 유기 용매로 더욱 추출하여 얻어진 유기 용매의 분획물일 수 있으나 이에 제한되는 것은 아니며, 예컨대, 상기 유기 용매는 헥산, 메틸렌클로라이드, 에틸 아세테이트, n-부탄올 등일 수 있다. 상기의 방법으로 추출한 추출물 또는 그 추출물의 분획물은 그대로 사용할 수도 있으나, 여과 후 농축하여 엑기스 형태로 사용할 수 있으며, 농축 후 동결 건조하여 동결건조물의 형태로서 사용할 수 있다. In the present specification, the "fraction" of weasel is meant a fraction obtained by further extracting the extract of weasel, obtained by a method self-explanatory to a glucose meter as mentioned above. Methods known in the art can be used without limitation to obtain the fraction. Specifically, the fraction may be a fraction of an organic solvent obtained by further extracting the weasel extract with a low polarity organic solvent, but is not limited thereto. For example, the organic solvent is hexane, methylene chloride, ethyl acetate, n-butanol Etc. The extract extracted by the above method or a fraction of the extract may be used as it is, but may be concentrated after filtration and used in the form of an extract, or freeze-dried after concentration and used as a freeze-dried product.
본 발명의 일 관점인 조성물에 있어서, 상기 족제비싸리 분획물은 족제비싸리의 메틸렌클로라이드 분획물, 헥산 분획물, 에틸아세테이트 분획물, 부탄올 분획물 또는 물 분획물일 수 있고, 족제비싸리 종자(열매)의 분획물일 수 있다. In the composition of one aspect of the present invention, the weasel bissari fraction may be a methylene chloride fraction, hexane fraction, ethyl acetate fraction, butanol fraction or water fraction of weasel bissari, and may be a fraction of weasel seed (fruit).
본 발명의 일 관점인 조성물에 있어서, 상기 조성물은 피부 주름을 개선, 피부 주름의 생성을 지연, 또는 피부 주름 생성을 예방할 수 있다. In the composition of one aspect of the present invention, the composition can improve skin wrinkles, delay the creation of skin wrinkles, or prevent the creation of skin wrinkles.
본 발명의 일 관점인 조성물에 있어서, 상기 조성물은 피부 탄력을 개선시킬 수 있다. In the composition of one aspect of the present invention, the composition may improve skin elasticity.
본 발명의 일 관점인 조성물에 있어서, 상기 조성물은 메탈로프로테아제, 젤라티네이즈 또는 엘라스타제의 합성을 억제하거나 이들의 활성을 저해시킬 수 있다. In the composition of one aspect of the present invention, the composition may inhibit the synthesis of metalloprotease, gelatinase, or elastase or inhibit their activity.
피부 진피층의 섬유아세포(fibroblast)에서 생성되는 콜라겐은 세포 외 기질(extracellular matrix)의 주요 구성 성분으로서 피부의 기계적 견고성 확보, 결합조직의 저항력 유도, 조직의 결합 및 세포 접착의 지탱 등 중요한 기능을 한다. 그러나 노화가 진행됨에 따라 섬유아세포의 기능이 저하되어 콜라겐의 생성량이 감소되고, 콜라겐을 분해하는 효소인 기질 금속단백질 분해효소(matrix metalloproteinase, MMP)의 발현이 촉진되어 콜라겐의 감소를 촉진한다. Collagen produced from fibroblasts in the dermal layer of the skin is a major component of the extracellular matrix and plays an important role in securing the skin's mechanical firmness, inducing resistance to connective tissues, and supporting tissue binding and cell adhesion. . However, as aging progresses, the function of fibroblasts decreases, resulting in a decrease in the amount of collagen produced, and the expression of matrix metalloproteinase (MMP), an enzyme that degrades collagen, is promoted to promote the reduction of collagen.
엘라스틴은 피부의 탄력을 유지하는 데 영향을 주는 인자이며, 콜라겐과 가교 결합을 형성하여 피부 매트릭스를 구성한다. 엘라스틴은 세포 내에서 트로포엘라스틴 (Tropoelastin)이라는 폴리펩타이드로 합성된 다음, 세포 외에서 트로포엘라스틴 간의 교차 결합을 통하여 2차 또는 3차원적인 탄성을 가지게 된다. 그런데 노화가 진행됨에 따라, 엘라스틴 섬유의 결핍과 응집 또는 엘라스틴 분해 효소인 엘라스테이즈(elastase)의 활성이 급격히 증가하여 엘라스틴의 그물망 구조를 깨뜨림에 따라 피부에 주름이 생기고 피부 탄력을 저하시킨다.Elastin is a factor that affects maintaining the elasticity of the skin, and it forms a cross-link with collagen to form the skin matrix. Elastin is synthesized as a polypeptide called Tropoelastin in the cell, and then has secondary or three-dimensional elasticity through cross-linking between tropoelastins outside the cell. However, as aging progresses, the deficiency and aggregation of elastin fibers or the activity of the elastin-degrading enzyme, elastase, increases rapidly, breaking the network structure of elastin, causing wrinkles and lowering skin elasticity.
본 발명의 일 관점인 조성물은 또한 메탈로프로테아제, 젤라티네이즈 또는 엘라스타제의 합성 또는 활성과 관계된 업스트림(up-stream)에 관여하는 효소나 단백질 등 생체 물질을 조절할 수 있다. The composition as an aspect of the present invention may also control biomaterials such as enzymes or proteins involved in the upstream (up-stream) related to the synthesis or activity of metalloprotease, gelatinase, or elastase.
본 발명은 다른 관점에서 족제비싸리 추출물을 유효성분으로 포함하는, 보습용 조성물에 관한 것으로, 본 발명의 조성물은 피부 장벽 기능을 강화시키고 피부 각질형성세포의 분화를 유도시킬 수 있다. 따라서 표피 분화의 불완전함으로 생기는 피부건조증, 아토피 또는 건선 등을 예방, 개선 또는 치료하기 위해 유용하게 사용할 수 있다.In another aspect, the present invention relates to a composition for moisturizing, comprising a weasel extract as an active ingredient, and the composition of the present invention can enhance skin barrier function and induce differentiation of skin keratinocytes. Therefore, it can be usefully used to prevent, improve, or treat dry skin, atopy, or psoriasis caused by incomplete epidermal differentiation.
본 발명의 일 관점인 조성물은 필라그린 또는 인볼루크린의 합성을 촉진시키거나 이들의 활성을 증진시킬 수 있다. The composition, which is an aspect of the present invention, may promote the synthesis of filaggrin or involukrin or enhance their activity.
본 발명의 일 관점인 조성물은 또한 아쿠아포린의 발현을 증가시킬 수 있다. The composition, which is one aspect of the present invention, can also increase the expression of aquaporin.
본 발명의 일 관점인 조성물은 또한 필라그린 또는 인볼루크린의 합성 또는 활성과 관계된 업스트림(up-stream)에 관여하는 효소나 단백질 등 생체 물질을 조절할 수 있고, 아쿠아포린의 발현 등과 관계된 업스트림(up-stream)에 관여하는 효소나 단백질 등 생체 물질을 조절할 수 있다. The composition as an aspect of the present invention can also regulate biological substances such as enzymes or proteins involved in the upstream (up-stream) related to the synthesis or activity of filaggrin or involukrin, and upstream (up) related to the expression of aquaporin, etc. -stream) can control biological substances such as enzymes and proteins.
본 발명의 일 관점인 조성물은 조성물 총 중량에 대하여 0.001 내지 10중량%의 족제비싸리 추출물을 포함할 수 있다. 상기 족제비싸리 추출물이 0.001중량% 미만이면 상기 언급한 각종 효과가 미미하게 나타나고, 10중량%를 초과하여 포함하면 함유량 증가에 따른 뚜렷한 효과의 증가가 나타나지 않고 다른 성분의 함량비에 영향을 미치기 때문이다. 상기와 같은 관점에서 본 발명의 조성물은 족제비싸리 추출물을 0.001 내지 10 중량%, 0.005 내지 9 중량%, 0.01 내지 8 중량%, 0.05 내지 7 중량% 또는 0.1 내지 6 중량%로 포함할 수 있다.The composition as an aspect of the present invention may include 0.001 to 10% by weight of a weasel extract based on the total weight of the composition. This is because when the amount of the weasel extract is less than 0.001% by weight, the above-mentioned various effects are insignificant, and when the content exceeds 10% by weight, there is no obvious increase in effect due to the increase in content, and the content ratio of other ingredients is affected. . In view of the above, the composition of the present invention may include 0.001 to 10% by weight, 0.005 to 9% by weight, 0.01 to 8% by weight, 0.05 to 7% by weight, or 0.1 to 6% by weight of the weasel extract.
본 발명의 일 관점인 조성물에 있어서, 상기 조성물은 화장료 조성물일 수 있다. In the composition of one aspect of the present invention, the composition may be a cosmetic composition.
본 발명에 따른 피부 외용제 조성물을 화장료의 형태로 제형화할 경우, 유연화장수, 수렴화장수, 영양화장수, 아이 크림, 영양 크림, 마사지 크림, 클렌징 크림, 클렌징 폼, 클렌징 워터, 파우더, 에센스 또는 팩 등의 형태로 제형화될 수 있으며, 그 제형이 특별히 한정되는 것은 아니다. 또한, 본 발명에 의한 조성물은 지방 물질, 유기용매, 용해제, 농축제, 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제, 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품학 또는 피부과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 상기 보조제는 화장품학 또는 피부과학 분야에서 일반적으로 사용되는 양으로 도입된다. 또한, 본 발명의 조성물은 피부 개선 효과를 증가시키기 위하여 피부 흡수 촉진 물질을 함유할 수 있다.When the composition for external application for skin according to the present invention is formulated in the form of a cosmetic, such as softening lotion, astringent lotion, nutritional lotion, eye cream, nutritional cream, massage cream, cleansing cream, cleansing foam, cleansing water, powder, essence or pack. It may be formulated in a form, and the formulation is not particularly limited. In addition, the composition according to the present invention is a fatty substance, an organic solvent, a solubilizing agent, a thickening agent, a gelling agent, an emollient, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, ionic or non- Ionic emulsifiers, fillers, sequestering agents, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or any other ingredients commonly used in cosmetics and It may contain adjuvants commonly used in the field of cosmetology or dermatology. The adjuvant is introduced in an amount generally used in the field of cosmetology or dermatology. In addition, the composition of the present invention may contain a skin absorption promoting material in order to increase the skin improvement effect.
본 발명의 일 관점인 조성물에 있어서, 상기 조성물은 피부 외용제 조성물일 수 있다. In the composition of one aspect of the present invention, the composition may be a composition for external application for skin.
본 발명의 조성물은 피부 외용제 조성물일 수 있고, 보다 구체적으로는 항산화용 피부 외용제 조성물로서 사용될 수 있으며 이는 유기라디칼인 DPPH의 산화를 억제시킴으로서 우수한 항산화 효과를 제공할 수 있다. 또한, 본 발명의 조성물은 항노화용 피부 외용제 조성물로서 사용될 수 있으며 이는 피부내 콜라게나제의 발현을 효과적으로 억제함으로써 피부 내의 콜라겐 분해를 감소시켜 피부 탄력을 증진시키고 주름을 개선시키는 항노화 효과가 뛰어나다. 또한, 본 발명의 조성물은 미백용 피부 외용제 조성물로서 사용될 수 있으며, 이는 멜라닌의 생성을 억제함으로써 우수한 미백 효과를 제공할 수 있다. 나아가, 본 발명의 조성물은 보습용 피부 외용제 조성물로서 사용될 수 있으며, 이는 피부 장벽 기능을 강화시키고 피부 각질형성세포의 분화를 유도시킬 수 있다. 따라서 표피 분화의 불완전함으로 생기는 피부건조증 또는 건선 등을 예방 또는 개선하는 피부 외용제 조성물로 유용하게 사용될 수 있다.The composition of the present invention may be a composition for external application for skin, and more specifically, may be used as a composition for external application for skin for antioxidant, which can provide excellent antioxidant effect by inhibiting oxidation of DPPH, an organic radical. In addition, the composition of the present invention can be used as a composition for external application for skin for anti-aging, which effectively inhibits the expression of collagenase in the skin, thereby reducing collagen breakdown in the skin, improving skin elasticity and improving wrinkles. In addition, the composition of the present invention can be used as a composition for external application for skin for whitening, which can provide an excellent whitening effect by suppressing the production of melanin. Further, the composition of the present invention can be used as a composition for external application for skin for moisturizing, which can strengthen the skin barrier function and induce the differentiation of skin keratinocytes. Therefore, it can be usefully used as a composition for external application for skin that prevents or ameliorates dry skin or psoriasis caused by incomplete epidermal differentiation.
본 발명에 따른 피부 외용제 조성물을 화장료의 형태로 제형화할 경우, 유연화장수, 수렴화장수, 영양화장수, 아이 크림, 영양 크림, 마사지 크림, 클렌징 크림, 클렌징 폼, 클렌징 워터, 파우더, 에센스 또는 팩 등의 형태로 제형화될 수 있으며, 그 제형이 특별히 한정되는 것은 아니다. 또한, 본 발명에 의한 조성물은 지방 물질, 유기용매, 용해제, 농축제, 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제, 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품학 또는 피부과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 상기 보조제는 화장품학 또는 피부과학 분야에서 일반적으로 사용되는 양으로 도입된다. 또한, 본 발명의 조성물은 피부 개선 효과를 증가시키기 위하여 피부 흡수 촉진 물질을 함유할 수 있다.When the composition for external application for skin according to the present invention is formulated in the form of a cosmetic, such as softening lotion, astringent lotion, nutritional lotion, eye cream, nutritional cream, massage cream, cleansing cream, cleansing foam, cleansing water, powder, essence or pack. It may be formulated in a form, and the formulation is not particularly limited. In addition, the composition according to the present invention is a fatty substance, an organic solvent, a solubilizing agent, a thickening agent, a gelling agent, an emollient, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, ionic or non- Ionic emulsifiers, fillers, sequestering agents, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or any other ingredients commonly used in cosmetics and It may contain adjuvants commonly used in the field of cosmetology or dermatology. The adjuvant is introduced in an amount generally used in the field of cosmetology or dermatology. In addition, the composition of the present invention may contain a skin absorption promoting material in order to increase the skin improvement effect.
본 발명의 일 관점인 조성물에 있어서, 상기 조성물은 약학적 조성물일 수 있다. In the composition of one aspect of the present invention, the composition may be a pharmaceutical composition.
본 발명에 따른 조성물을 의약품에 적용할 경우에는, 상기 조성물을 유효성분으로 하여 상용되는 무기 또는 유기의 담체를 가하여 고체, 반고체 또는 액상의 형태로 경구 투여제 혹은 비경구 투여제로 제제화 할 수 있다.When the composition according to the present invention is applied to a pharmaceutical product, the composition may be formulated as an oral or parenteral administration in a solid, semi-solid or liquid form by adding a commercially available inorganic or organic carrier using the composition as an active ingredient.
상기 경구 투여를 위한 제재로서는 정제, 환제, 과립제, 연, 경 캡슐제, 산제, 세립제, 분제, 유탁제, 시럽제, 펠렛제 등을 들 수 있다. 또한, 상기 비경구 투여를 위한 제재로는 주사제, 점적제, 연고, 로션, 스프레이, 현탁제, 유제, 좌제 등을 들 수 있다. 본 발명의 유효성분을 제제화하기 위해서는 상법에 따라서 실시하면 용이하게 제제화할 수 있으며 계면활성제, 부형제, 착색료, 향신료, 보존료, 안정제, 완충제, 현탁제, 기타 상용하는 보조제를 적당히 사용할 수 있다.Examples of the formulation for oral administration include tablets, pills, granules, soft capsules, hard capsules, powders, fine granules, powders, emulsions, syrups, pellets, and the like. In addition, the preparations for parenteral administration include injections, drops, ointments, lotions, sprays, suspensions, emulsions, and suppositories. In order to formulate the active ingredient of the present invention, it can be easily formulated if carried out according to conventional methods, and surfactants, excipients, coloring agents, spices, preservatives, stabilizers, buffers, suspensions, and other commonly used auxiliary agents can be appropriately used.
본 발명에 따른 상기 약학 조성물은 경구, 비경구, 직장, 국소, 경피, 정맥 내, 근육 내, 복강 내, 피하 등으로 투여될 수 있다. The pharmaceutical composition according to the present invention may be administered orally, parenteral, rectal, topical, transdermal, intravenous, intramuscular, intraperitoneal, subcutaneous, and the like.
또한, 상기 활성성분의 투여량은 치료 받을 대상의 연령, 성별, 체중과, 치료할 특정 질환 또는 병리 상태, 질환 또는 병리 상태의 심각도, 투여경로 및 처방자의 판단에 따라 달라질 것이다. 이러한 인자에 기초한 투여량 결정은 당업자의 수준 내에 있다. 일반적인 투여량은 0.001 mg/kg/일 내지 2000 mg/kg/일, 보다 구체적으로는 0.5 mg/kg/일 내지 1500 mg/kg/일이다.In addition, the dosage of the active ingredient will vary depending on the age, sex, and weight of the subject to be treated, the specific disease or pathological state to be treated, the severity of the disease or pathological state, the route of administration, and the judgment of the prescriber. Dosage determination based on these factors is within the level of one of skill in the art. Typical dosages are 0.001 mg/kg/day to 2000 mg/kg/day, more specifically 0.5 mg/kg/day to 1500 mg/kg/day.
본 발명의 일 관점인 조성물에 있어서, 상기 조성물은 건강식품 조성물일 수 있다. 본 발명에 따른 조성물은 포함하는 다양한 형태의 식품 첨가제 또는 기능성 식품을 제공한다. 상기 조성물을 포함하는 발효유, 치즈, 요구르트, 주스, 생균제제 및 건강보조식품 등으로 가공될 수 있으며, 그 외 다양한 식품 첨가제의 형태로 사용될 수 있다. In the composition of one aspect of the present invention, the composition may be a health food composition. The composition according to the present invention provides various types of food additives or functional foods, including. It may be processed into fermented milk, cheese, yogurt, juice, probiotics, health supplements, etc. including the composition, and may be used in the form of various other food additives.
일실시예에서 상기 조성물은, 본 발명이 목적으로 하는 주 효과를 손상시키지 않는 범위 내에서 주 효과에 상승 효과를 줄 수 있는 다른 성분 등을 함유할 수 있다. 예를 들어, 물성 개선을 위하여 향료, 색소, 살균제, 산화방지제, 방부제, 보습제, 점증제, 무기염류, 유화제 및 합성 고분자 물질 등의 첨가제를 더 포함할 수 있다. 그 외에도, 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당 및 해초 엑기스 등의 보조 성분을 더 포함할 수도 있다. 상기 성분들은 제형 또는 사용 목적에 따라서 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 그 첨가량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 선택될 수 있다. 예를 들어, 상기 성분들의 첨가량은, 조성물 전체 중량을 기준으로, 0.01~5 중량%, 보다 구체적으로는 0.01~3 중량% 범위일 수 있다.In one embodiment, the composition may contain other components that can give a synergistic effect to the main effect within a range that does not impair the main effect targeted by the present invention. For example, additives such as fragrances, pigments, disinfectants, antioxidants, preservatives, moisturizers, thickeners, inorganic salts, emulsifiers, and synthetic polymer substances may be further included in order to improve physical properties. In addition, auxiliary components such as water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, and seaweed extract may be further included. The above ingredients may be appropriately selected and blended by a person skilled in the art according to the formulation or purpose of use, and the amount added may be selected within a range not impairing the object and effect of the present invention. For example, the amount of the components added may be in the range of 0.01 to 5% by weight, more specifically 0.01 to 3% by weight, based on the total weight of the composition.
본 발명에 따른 조성물의 제형은 용액, 유화물, 점성형 혼합물, 타블렛, 분말 등의 다양한 형태일 수 있으며, 이는 단순 음용, 주사 투여, 스프레이 방식 또는 스퀴즈 방식 등의 다양한 방법으로 투여될 수 있다.The formulation of the composition according to the present invention may be in various forms such as solutions, emulsions, viscous mixtures, tablets, powders, etc., which may be administered by various methods such as simple drinking, injection administration, spray method, or squeeze method.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다. Hereinafter, the present invention will be described in more detail through examples. These examples are for illustrative purposes only, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not construed as being limited by these examples.
이하 실시예의 족제비싸리는 대관령 고랭지에서 자생하고 있는 것을 사용하였다.The weasel of the following examples was used that grows wild in the highlands of Daegwallyeong.
[[ 실시예Example 1] 족제비싸리 추출물의 제조 1] Preparation of weasel extract
족제비싸리 종자 100 g을 100 % 메탄올 1 L에 담구어 3 시간 동안 환류 추출하였다. 이를 3회 반복하여 얻은 추출액을 감압 건조하고 농축하여 농축물 14.7 g을 얻었다.100 g of weasel seeds were immersed in 1 L of 100% methanol and extracted under reflux for 3 hours. The extract obtained by repeating this three times was dried under reduced pressure and concentrated to obtain 14.7 g of a concentrate.
[[ 실시예Example 2] 족제비싸리 추출물로부터 2] From weasel extract 분획물의Fraction 제조 Produce
상기 실시예 1에서 제조한 족제비싸리 종자의 메탄올 추출물을 일반적인 극성에 따른 용매분획법의 단계를 따라 분획하였다. 메탄올추출물 10 g을 물 500 ml에 현탁한 후 메틸렌클로라이드로 진탕추출하고, 정치하여 메틸렌클로라이드층을 분리하였다. 2회 더 분획한 후 메틸렌클로라이드층을 모두 합하여 감압건조하여 메틸렌클로라이드분획(<2M>)을 얻었다. 이어서 남은 물층에 헥산(<2H>), 에틸아세테이트(<2E>), 부탄올(<2B>)로 차례차례 분획하였다. 위 분획을 감압농축하여, 메틸렌클로라이드분획 0.8 g, 헥산분획 1.1 g, 에틸아세테이트분획 2.1 g, 부탄올분획 2.5 g을 수득하였다. The methanol extract of the weasel seed prepared in Example 1 was fractionated according to the steps of the solvent fractionation method according to the general polarity. 10 g of the methanol extract was suspended in 500 ml of water, extracted by shaking with methylene chloride, and allowed to stand to separate the methylene chloride layer. After fractionating twice, the methylene chloride layers were combined and dried under reduced pressure to obtain a methylene chloride fraction (<2M>). Subsequently, the remaining water layer was sequentially fractionated with hexane (<2H>), ethyl acetate (<2E>), and butanol (<2B>). The above fractions were concentrated under reduced pressure to obtain 0.8 g of methylene chloride fraction, 1.1 g of hexane fraction, 2.1 g of ethyl acetate fraction, and 2.5 g of butanol fraction.
[ 실험예 1] 자외선에 의한 매트릭스 메탈로프로테이나제 -1 ( MMP -1)의 생합성 억제 효능 및 콜라겐 분해 억제 측정 [ Experimental Example 1] Measurement of biosynthesis inhibition efficacy and collagen degradation inhibition of matrix metalloproteinase- 1 ( MMP- 1) by ultraviolet rays
신생아 포피에서 직접 분리한 1차세포(primary cell)인 인체 섬유아세포(Lonza, Switzerland)를 104개의 농도로 48공 평판배양기에 배양하고, 24시간 후에 자외선 B를 30 mJ/cm2로 조사한 후 표 1의 시험물질 각각을 10 ug/ml씩 함유한 배지로 갈아주었다. 배양 2일째 상등액을 수확(harvest)해서 ELISA(AP biotech RPN2610) 방법을 사용하여 생성된 MMP-1의 양을 정량하였다. 또한 동일한 상등액을 이용하여 분해되지 않고 남아 있는 프로콜라겐의 양을 ELISA(Takara MK101)방법을 사용하여 정량하였다. 각각의 값들은 자외선 B만을 조사한 대조군의 값을 100으로 하여 상대값으로 나타내었다 (표 1 및 도 1). Human fibroblasts (Lonza, Switzerland), which are the primary cells directly isolated from the newborn foreskin, were cultured in a 48-hole plate incubator at a concentration of 10 4 and irradiated with ultraviolet B at 30 mJ/cm 2 after 24 hours. Each of the test substances in Table 1 was changed to a medium containing 10 ug/ml. On the second day of culture, the supernatant was harvested and the amount of MMP-1 produced was quantified using the ELISA (AP biotech RPN2610) method. In addition, the amount of procollagen remaining without decomposition using the same supernatant was quantified using the ELISA (Takara MK101) method. Each of the values was expressed as a relative value with the value of the control group irradiated with only ultraviolet B as 100 (Table 1 and FIG. 1).
그 결과, 표 1및 도 1 에 나타난 바와 같이, 족제비싸리 추출물 또는 그의 분획물을 처리함에 의해 타입 I 콜라게나제인 매트릭스 메탈로프로테아제(MMP)의 생합성을 감소시키고, 또한 이에 따라 프로콜라겐의 분해도 방지함을 알 수 있었다. As a result, as shown in Table 1 and FIG. 1, by treating the weasel extract or its fractions, the biosynthesis of type I collagenase-in matrix metalloprotease (MMP) is reduced, and accordingly, the decomposition of procollagen is also prevented. And it was found.
[[ 실험예Experimental example 2] 2]
MMPMMP -1의 생합성 억제 효능 측정Measurement of the biosynthesis inhibitory efficacy of -1
신생아 포피에서 직접 분리한 1차세포(primary cell)인 인체 섬유아세포 (Lonza, Switzerland) 를 104개의 농도로 48공 평판배양기에 배양하고, 24시간 후에 TNF-α 10 ng/ml과 각각의 시험물질 10 ug/ml씩을 함유한 배지로 갈아주었다. 배양 2일째 상등액을 수확(harvest)해서 ELISA(AP biotech RPN2610) 방법을 사용하여 생성된 타입 I 콜라게나제의 양을 정량하였다. 각각의 값들은 TNF-α 만을 처리한 대조군의 값을 100으로 하여 상대값으로 나타내었다 (표 2 및 도 2).Human fibroblasts (Lonza, Switzerland), which are the primary cells directly isolated from the newborn foreskin, were cultured in a 48-hole plate incubator at 10 4 concentrations, and after 24 hours, TNF-
상기 표 2및 도 2에 의해 알 수 있는 바와 같이, 족제비싸리 추출물 또는 그의 분획물은 TNF-α가 초래시키는 매트릭스 메탈로프로테아제(MMP)의 생합성을 감소시킬 수 있음을 확인하였다. As can be seen from Table 2 and FIG. 2, it was confirmed that the weasel extract or a fraction thereof can reduce the biosynthesis of matrix metalloprotease (MMP) caused by TNF-α.
[ 실험예 3] 젤라티네이즈 A( MMP -9)와 젤라티네이즈 B( MMP -2)의 생합성 억제 효능 및 활성억제 효능 측정 [Experimental example 3] T gelatinase tyrosinase A (MMP -9) and biosynthesis inhibiting efficacy and activity inhibitory effect measurement of gelatinase tea tyrosinase B (MMP -2)
인체각질형성세포(Deutsches Krebsforschungszentrum 의 Fusenig박사에게 공여받은 인체각질형성세포(HaCaT))를 1 X 104 개의 농도로 24공 평판배양기에 배양하고, 24시간 후에 자외선 B를 30 mJ/cm2로 조사한 후, 표 3의 시험물질 각각을 10 ug/ml씩 함유한 배지로 갈아주었다. 배양 48 시간 후 상등액을 수확(harvest)해서 젤라틴젤을 이용한 자이모그래피(Zymography)를 한 후 생성되어 분비된 MMP-2와 MMP-9의 양을 덴시토미터(Image J is a public domain Java image processing program inspired by NIH Image)로 측정하여 정량하였다. Human keratinocytes (Human keratinocytes (HaCaT) donated by Dr. Fusenig of Deutsches Krebsforschungszentrum) were cultured in a 24-hole plate incubator at a concentration of 1 X 10 4 and irradiated with ultraviolet B at 30 mJ/cm 2 after 24 hours. Thereafter, each of the test substances in Table 3 was changed to a medium containing 10 ug/ml. After 48 hours of incubation, the supernatant was harvested, zymography was performed using gelatin gel, and the amount of MMP-2 and MMP-9 produced and secreted was measured with a densitometer (Image J is a public domain Java image). processing program inspired by NIH Image).
아울러, 상기 활성에 따른 영향을 알아보기 위해, 상기 상등액 일정량을 젤라틴젤에 내린 후 30분 동안 buffer A 에 담가 renaturation 시킨 후, buffer B와 시료를 동시에 처리하여 develop 한 후 활성이 억제된 정도를 덴시토미터로 측정하여 정량하였다. 각각의 값들은 자외선 B만을 조사한 대조군의 값을 100으로 하여 상대값으로 나타내었다 (표 3 및 도 3 내지 4).In addition, in order to find out the effect of the activity, a certain amount of the supernatant is lowered in a gelatin gel, soaked in buffer A for 30 minutes for renaturation, and then developed by processing buffer B and a sample at the same time to determine the degree of inhibition of activity It was quantified by measuring with a cytometer. Each of the values was expressed as a relative value with the value of the control group irradiated with only ultraviolet B as 100 (Table 3 and FIGS. 3 to 4).
그 결과, 표 3과 도3 및 4 에 나타난 바와 같이, 족제비싸리 추출물 또는 그의 분획물은 MMP-2 와 MMP-9의 생합성 또는 활성을 저해하여 표피와 진피의 경계부를 보호하고 분해를 방지하여 피부주름감소, 탄력증진, 피부 밀착력 강화라는 효과를 가져올 수 있음을 확인하였다. As a result, as shown in Table 3 and Figs. 3 and 4, the weasel extract or its fraction inhibits the biosynthesis or activity of MMP-2 and MMP-9 to protect the boundary between the epidermis and the dermis and prevent decomposition, resulting in skin wrinkles. It was confirmed that it can have the effect of reducing, increasing elasticity, and strengthening skin adhesion.
[[ 실험예Experimental example 4] 4] 엘라스타제Elastase ( ( ElastaseElastase ) 활성에 미치는 영향 측정) Measurement of the effect on activity
사람 백혈구 엘라스타제(HNE, sigma, E8140 (1 U))는 1 vial에 0.2M Tris-Cl(pH8.0)를 1ml 첨가하여 1U/ml로 만들고, 기질(N-(Methoxysuccinyl)-Ala-Ala-Pro-Val 4-nitroanilide (M4765) MW 590.6) 은 DMSO에 120 mM로 만들어 놓은 후, 사용 직전에 0.2 M Tris-Cl (pH8.0)로 1:20으로 희석하여 6 mM로 만들고 최종적으로 2 mM만을 첨가하였다. 96 공 플레이트에서 0.2 M Tris-Cl, 아래 표 4의 각각의 시험물 및 효소를 함께 10분간 두고 기질을 넣은 후 실온에서 30분간 두어 반응시킨 후 분해되어 나온 p-nitroanilide의 양을 405 nm에서의 흡광도로 측정하였다. Human leukocyte elastase (HNE, sigma, E8140 (1 U)) is made to 1 U/ml by adding 1 ml of 0.2M Tris-Cl (pH 8.0) to 1 vial, and the substrate (N-(Methoxysuccinyl)-Ala- Ala-Pro-Val 4-nitroanilide (M4765) MW 590.6) is prepared to 120 mM in DMSO, and then diluted 1:20 with 0.2 M Tris-Cl (pH 8.0) to 6 mM immediately before use. Only 2 mM was added. Put 0.2 M Tris-Cl, each of the test products and enzymes in Table 4 below together for 10 minutes on a 96 empty plate, add the substrate, and leave for 30 minutes at room temperature to react, and then adjust the amount of p-nitroanilide decomposed at 405 nm. It was measured by absorbance.
아울러, 돼지 췌장 엘라스타제(PPE, sigma (E1250 (19mg/ml))는 0.2M Tris-Cl(pH8.0)에 3X로 만든다(10ug/ml). 기질 (N-Succinyl-Ala-Ala-Ala-p-nitroanilide (S4760) MW;451.4)은 0.2 M Tris-Cl(pH8.0)에 6mM로 만들어 놓은 후, 최종적으로 2mM로 첨가하였다. 96 공 플레이트에 0.2 M Tris-Cl, 각각의 시험물 및 효소를 넣고 10분간 두고 기질을 넣은 후 실온에서 30분간 두어 반응시킨 후 분해되어 나온 p-nitroanilide의 양을 405 nm에서의 흡광도로 측정한 결과 아래 표 4 및 도 5를 얻었다. In addition, porcine pancreatic elastase (PPE, sigma (E1250 (19mg/ml)) is made 3X in 0.2M Tris-Cl (pH8.0) (10ug/ml) Substrate (N-Succinyl-Ala-Ala-) Ala-p-nitroanilide (S4760) MW;451.4) was made up to 6 mM in 0.2 M Tris-Cl (pH 8.0), and then finally added to 2 mM. 0.2 M Tris-Cl in 96 blank plates, each test Water and enzyme were added, left for 10 minutes, substrate was added, and then left at room temperature for 30 minutes to react, and the amount of decomposed p-nitroanilide was measured by absorbance at 405 nm to obtain Tables 4 and 5 below.
저해율(%)Human Leukocyte Elastase
Inhibition rate (%)
저해율(%)Porcine Pancreas Elastase
Inhibition rate (%)
그 결과, 표 4및 도 5에 나타난 바와 같이, 족제비싸리 추출물 또는 그의 분획물은 엘라스타제 활성을 저해하여 피부탄력의 저하를 예방할 수 있음을 확인할 수 있었다. As a result, as shown in Table 4 and 5, it was confirmed that the weasel bissari extract or a fraction thereof inhibited the elastase activity, thereby preventing a decrease in skin elasticity.
[[ 실험예Experimental example 5] 5]
필라그린Pillar Green ( ( filaggrinfilaggrin ) 및 ) And 인볼루크린Involukrin ( ( involucrininvolucrin ) 의 발현 측정) Expression measurement
신생아 표피에서 직접 분리한 인체 각질형성세포(Lonza, Switzerland) 를 106개의 농도로 100 파이 디쉬(dish)에 배양하고, 각 추출물 및 분획물을 10 ug/ml 포함한 배지로 교체하였다. 배양 24 시간 후 세포를 수확(harvest)해서 단백질을 얻었으며 단백질량은 BCA 키트(Pierce Biotechnology, USA)를 사용하여 정량하였다. 웨스턴블랏(Western Blot) 방법을 사용하여 생성된 필라그린(filaggrin)과 인볼루크린(Involucrin)의 양을 정량하였다. 상기 웨스턴블랏은 레인(lane) 당 30 ug의 단백질을 SDS-PAGE 겔에 적재(loading)하여 전기영동한 후 단백질 이동키트(transfer kit)(Invitrogen, USA)을 사용하여 PVDF 막(membrane)(Amersham, USA)으로 단백질을 이동시켰다. 이동 후 1차 항체로 각각 필라크린과 인볼루크린에 대한 항체(Santacruz Biotechnology, USA)를 37℃에서 1시간 정도 붙여주고, PBS로 3회 세척한 후 HRP가 붙은 2차 항체를 37℃에서 1시간 정도 붙여주고, PBS로 3회 세척 후 ECL 키트을 사용하여 그 발광정도를 필름에 노출시키고, 밴드의 강도를 덴시토미터(densitometer)를 사용하여 정량하였다. 각각의 값은 무처리군의 값을 100으로 하여 얻은 상대값이다. Human keratinocytes (Lonza, Switzerland) isolated directly from the neonatal epidermis were cultured in 100 pie dishes at a concentration of 10 6 , and each extract and fraction were replaced with a medium containing 10 ug/ml. After 24 hours of culture, cells were harvested to obtain protein, and the amount of protein was quantified using a BCA kit (Pierce Biotechnology, USA). The amount of filaggrin and Involucrin produced was quantified using the Western Blot method. The western blot was subjected to electrophoresis by loading 30 ug of protein per lane on an SDS-PAGE gel, and then a PVDF membrane (Amersham) using a protein transfer kit (Invitrogen, USA). , USA). After transfer, attach the antibodies against Pilacrine and Involucrin (Santacruz Biotechnology, USA) as the primary antibodies at 37°C for about 1 hour, and after washing three times with PBS, the secondary antibody with HRP was added at 37°C. After about a period of time and washing with PBS three times, the degree of luminescence was exposed to the film using an ECL kit, and the intensity of the band was quantified using a densitometer. Each value is a relative value obtained by setting the value of the untreated group as 100.
그 결과, 상기 표 5 및 도 6에 나타난 바와 같이, 족제비싸리 추출물 또는 분획물은 각질형성세포에서 천연보습인자인 필라그린 및 인볼루크린의 생합성량을 증가시킬 수 있음을 확인할 수 있었다. As a result, as shown in Tables 5 and 6, it was confirmed that the extract or fraction of weasel bissari could increase the biosynthetic amount of natural moisturizing factors, Pilagrine and Involukrin, in keratinocytes.
[[ 실험예Experimental example 6] 6]
아쿠아포린Aquaporin 3 유전자의 발현 변화 측정 3 Measurement of changes in gene expression
신생아 표피에서 직접 분리한 인체 각질형성세포(Lonza, Switzerland) 를 106개의 농도로 100 파이 디쉬(dish)에 배양하고, 각 추출물 또는 분획물을 10 ug/ml 포함한 배지로 교체하였다. 24시간 후에 트리졸(trizol)을 이용하여 전체 RNA를 추출하고, RT-PCR을 통해 Aquaporin 3 유전자의 발현 정도를 확인하였다. 상기 RT-PCR에서 역전사(reverse transcription)는 시중에 판매되는 키트(reverse transcription system, Promega)를 사용하여 수행하였으며, PCR은 변성(denaturation)은 94℃, 1분, 풀림(annealing)은 54℃, 1분, 연장(extension)은 72℃, 1분씩 총 30 사이클(cycle)로 수행하였다. PCR에 사용된 프라이머(primer)들은 아래와 같다.Human keratinocytes (Lonza, Switzerland) isolated directly from the neonatal epidermis were cultured in 100 pie dishes at a concentration of 10 6 , and each extract or fraction was replaced with a medium containing 10 ug/ml. After 24 hours, total RNA was extracted using trizol, and the expression level of Aquaporin 3 gene was confirmed through RT-PCR. In the RT-PCR, reverse transcription was performed using a commercially available kit (reverse transcription system, Promega), and PCR was performed at 94°C for denaturation, 1 minute, and 54°C for annealing, 1 minute, extension (extension) was carried out at 72 ℃, a total of 30 cycles (1 minute). The primers used in PCR are as follows.
Aquaporin 3Aquaporin 3
포워드(forward) 5' gacagaaggagctggtgtcc 3'Forward 5'gacagaaggagctggtgtcc 3'
리버스(reverse) 5' atgaggatgcccagagtgac 3'Reverse 5'atgaggatgcccagagtgac 3'
GAPDHGAPDH
포워드(forward) 5' accacagtccatgccatcac 3'Forward 5'accacagtccatgccatcac 3'
리버스(reverse) 5' tccaccaccctgttgctgta 3'Reverse 5'tccaccaccctgttgctgta 3'
PCR 종료 후 생성된 생성물들을 아가로스겔 (Agarose gel)에 적재(loading)하여 전기영동시키고, 에티디움 브로마이드로 이를 염색한 후, 자외선 존재 하에서 생성된 밴드를 측정하고, 그 강도를 덴시토미터(densitometer)를 사용하여 정량하였다. 각각의 값은 무처리군을 100으로 하였을 때 이에 대한 상대값으로 나타내었다 (표 6 및 도 7).After completion of PCR, the generated products were loaded on an agarose gel and subjected to electrophoresis, stained with ethidium bromide, and then the band generated in the presence of ultraviolet rays was measured, and the intensity was measured with a densitometer ( densitometer). Each value was expressed as a relative value when the untreated group was set to 100 (Table 6 and FIG. 7).
발현량Aquaporin 3
Expression level
그 결과, 상기 표 6 및 도 7에서 나타나는 바와 같이 족제비싸리 추출물 또는 분획물의 처리에 의해 물 및 글리세린 이동에 관계된 단백질인 아쿠아포린의 유전자의 발현이 증가함을 확인할 수 있었다. As a result, it was confirmed that, as shown in Table 6 and FIG. 7, the expression of aquaporin, a protein related to water and glycerin migration, was increased by treatment of the weasel extract or fraction.
본 발명에 조성물은 하기와 같이 여러 가지 제형으로 응용 가능하지만, 이에 한정되는 것은 아니다.The composition in the present invention can be applied in various formulations as follows, but is not limited thereto.
[제제예 1] 정제[Formulation Example 1] Tablet
족제비싸리 추출물 또는 분획물 100 mg, 포도당 100 mg, 홍삼추출물 50 mg, 전분 96 mg 및 마그네슘 스테아레이트 4 mg을 혼합하고 30% 에탄올을 40 mg 첨가하여 과립을 형성한 후, 60℃에서 건조하고 타정기를 이용하여 정제로 타정하였다.After mixing 100 mg of weasel extract or fraction, 100 mg of glucose, 50 mg of red ginseng extract, 96 mg of starch, and 4 mg of magnesium stearate, and 40 mg of 30% ethanol were added to form granules, dried at 60°C and a tablet press Then, it was compressed into tablets.
[제제예 2] 과립제[Formulation Example 2] Granules
족제비싸리 추출물 또는 분획물 100 mg, 포도당 100 mg, 홍삼추출물 50 mg 및 전분 600 mg을 혼합하고 30% 에탄올을 100 mg 첨가하여 과립을 형성한 후, 60℃에서 건조하여 과립을 형성한 다음 포에 충진하였다. 내용물의 최종 중량은 1 g으로 하였다.After mixing 100 mg of weasel extract or fraction, 100 mg of glucose, 50 mg of red ginseng extract and 600 mg of starch, adding 100 mg of 30% ethanol to form granules, drying at 60°C to form granules, and then filling in a bag I did. The final weight of the contents was 1 g.
[제제예 3] 드링크제[Formulation Example 3] Drinks
족제비싸리 추출물 또는 분획물 100 mg, 포도당 10 g, 홍삼추출물 50 mg, 구연산 2 g 및 정제수 187.8 g을 혼합하고 병에 충진하였다. 내용물의 최종 용량은 200 ml로 하였다.100 mg of weasel extract or fraction, 10 g of glucose, 50 mg of red ginseng extract, 2 g of citric acid, and 187.8 g of purified water were mixed and filled into a bottle. The final volume of the contents was 200 ml.
[제제예 4] 건강 식품의 제조[Formulation Example 4] Preparation of healthy food
족제비싸리 추출물 또는 분획물.................................... 1000 ㎎ Weasel extract or fraction.............1000 ㎎
비타민 혼합물 Vitamin mixture
비타민 A 아세테이트.......................70 ㎍ Vitamin A acetate............70 ㎍
비타민 E ............................................ 1.0 ㎎ Vitamin E ............................................1.0 ㎎
비타민 B1........................................... 0.13 ㎎ Vitamin B1........................................... 0.13 mg
비타민 B2 .......................................... 0.15 ㎎ Vitamin B2 ................................0.15 mg
비타민 B6........................................... 0.5 ㎎ Vitamin B6........................................... 0.5 ㎎
비타민 B12......................................... 0.2 ㎍ Vitamin B12......................................... 0.2 ㎍
비타민 C............................................. 10 ㎎ Vitamin C............................................. 10 ㎎
비오틴.................................................. 10 ㎍ Biotin...................................... 10 ㎍
니코틴산아미드.................................. 1.7 ㎎ Nicotinic acid amide..................................1.7 mg
엽산...................................................... 50 ㎍ Folic acid................................................. ..... 50 ㎍
판토텐산 칼슘.................................... 0.5 ㎎ Calcium pantothenate...................................0.5 mg
무기질 혼합물 Mineral mixture
황산제1철.......................................... 1.75 ㎎ Ferrous sulfate.......................................... 1.75 mg
산화아연.............................................. 0.82 ㎎ Zinc oxide.............................................. 0.82 mg
탄산마그네슘...................................... 25.3 ㎎ Magnesium carbonate......................................25.3 mg
제1인산칼륨.......................................... 15 ㎎ Potassium Phosphate Monobasic.........................................15 ㎎
제2인산칼슘.......................................... 55 ㎎ Dicalcium Phosphate..........................................55 ㎎
구연산칼륨............................................ 90 ㎎ Potassium citrate............................................90 mg
탄산칼슘.............................................. 100 ㎎ Calcium carbonate..............................................100 mg
염화마그네슘..................................... 24.8 ㎎ Magnesium chloride.....................................24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.The composition ratio of the vitamin and mineral mixture is relatively suitable for health food, but it may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method. , Granules can be prepared, and used for preparing health food compositions according to conventional methods.
[제제예 5] 건강 음료의 제조 [Formulation Example 5] Preparation of healthy beverage
족제비싸리 추출물 또는 분획물 ................................ 1000 ㎎ Weasel extract or fraction ......................1000 ㎎
구연산..................................................... 1000 ㎎ Citric acid................................................. .... 1000 mg
올리고당..................................................... 100 g oligosaccharide................................................. .... 100 g
매실농축액..................................................... 2 g Plum Concentrate... ..... 2 g
타우린............................................................ 1 g Taurine............................ ........... 1 g
정제수를 가하여 전체......................... 900 ㎖ Total by adding purified water.........900 ml
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2ℓ용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다.After mixing the above ingredients according to a general health drink manufacturing method, stirring and heating at 85° C. for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 liter container, sealed and sterilized, and then stored in a refrigerator. It is used in the manufacture of health drink composition.
[제형예 1] 로션[Formulation Example 1] Lotion
[제형예 2] 크림[Formulation Example 2] Cream
[제형예 3] 팩[Formulation Example 3] Pack
[제형예 4] 미용액[Formulation Example 4] Essence
[제형예 5] 연고[Formulation Example 5] Ointment
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적 기술은 단지 바람직한 실시태양일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.As described above, specific parts of the present invention have been described in detail, and it is obvious that these specific techniques are only preferred embodiments for those of ordinary skill in the art, and the scope of the present invention is not limited thereby something to do. Accordingly, it will be said that the substantial scope of the present invention is defined by the appended claims and their equivalents.
<110> KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
<120> COMPOSITION CONTAINING AMORPHA FRUTICOSA EXTRACT
<130> 15P746/IND
<160> 4
<170> KopatentIn 2.0
<210> 1
<211> 20
<212> DNA
<213> Aquaporin 3-forward
<400> 1
gacagaagga gctggtgtcc 20
<210> 2
<211> 20
<212> DNA
<213> Aquaporin 3-reverse
<400> 2
atgaggatgc ccagagtgac 20
<210> 3
<211> 20
<212> DNA
<213> GAPDH-forward
<400> 3
accacagtcc atgccatcac 20
<210> 4
<211> 20
<212> DNA
<213> GAPDH-reverse
<400> 4
tccaccaccc tgttgctgta 20
<110> KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
<120> COMPOSITION CONTAINING AMORPHA FRUTICOSA EXTRACT
<130> 15P746/IND
<160> 4
<170> KopatentIn 2.0
<210> 1
<211> 20
<212> DNA
<213> Aquaporin 3-forward
<400> 1
Claims (12)
상기 조성물은 필라그린 또는 인볼루크린의 합성을 촉진시키거나 이들의 활성을 증진시키는, 보습용 화장료 조성물.The method according to claim 1,
Wherein said composition promotes the synthesis of pillar green or phosphorylcholine or promotes their activity.
상기 조성물은 아쿠아포린의 발현을 증가시키는, 보습용 화장료 조성물.The method according to claim 1,
Wherein the composition increases the expression of aquaporin.
상기 추출물은 에탄올 또는 메탄올 추출물인, 보습용 화장료 조성물.The method according to claim 1,
Wherein the extract is an ethanol or methanol extract.
상기 분획물은 헥산 분획물, 메틸렌클로라이드 분획물, 에틸 아세테이트 분획물 및 부탄올 분획물로 이루어진 군에서 선택되는 하나 이상인, 보습용 화장료 조성물.The method according to claim 1,
Wherein the fraction is at least one selected from the group consisting of hexane fraction, methylene chloride fraction, ethyl acetate fraction and butanol fraction.
상기 조성물은 조성물 총 중량에 대하여 0.001 내지 10중량%의 족제비싸리 추출물 또는 이의 분획물을 포함하는, 보습용 화장료 조성물.The method according to claim 1,
Wherein the composition comprises from 0.001 to 10% by weight of the fermented extract or fraction thereof, based on the total weight of the composition.
상기 조성물은 필라그린 또는 인볼루크린의 합성을 촉진시키거나 이들의 활성을 증진시키는, 보습용 건강식품 조성물.8. The method of claim 7,
Wherein the composition promotes the synthesis of pillar green or phosphorylcholine or promotes their activity.
상기 조성물은 아쿠아포린의 발현을 증가시키는, 보습용 건강식품 조성물.8. The method of claim 7,
Wherein said composition increases the expression of aquaporin.
상기 추출물은 에탄올 또는 메탄올 추출물인, 보습용 건강식품 조성물.8. The method of claim 7,
Wherein the extract is an ethanol or methanol extract.
상기 분획물은 헥산 분획물, 메틸렌클로라이드 분획물, 에틸 아세테이트 분획물 및 부탄올 분획물로 이루어진 군에서 선택되는 하나 이상인, 보습용 건강식품 조성물.8. The method of claim 7,
Wherein said fraction is at least one selected from the group consisting of hexane fraction, methylene chloride fraction, ethyl acetate fraction and butanol fraction.
상기 조성물은 조성물 총 중량에 대하여 0.001 내지 10중량%의 족제비싸리 추출물 또는 이의 분획물을 포함하는, 보습용 건강식품 조성물.8. The method of claim 7,
Wherein said composition comprises from 0.001 to 10% by weight of the fermentation broth extract or fraction thereof, based on the total weight of the composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150165755A KR20160008121A (en) | 2015-11-25 | 2015-11-25 | Composition containing amorpha fruticosa extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150165755A KR20160008121A (en) | 2015-11-25 | 2015-11-25 | Composition containing amorpha fruticosa extract |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020140081151A Division KR20160002539A (en) | 2014-06-30 | 2014-06-30 | Composition containing amorpha fruticosa extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160008121A true KR20160008121A (en) | 2016-01-21 |
Family
ID=55308598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150165755A KR20160008121A (en) | 2015-11-25 | 2015-11-25 | Composition containing amorpha fruticosa extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20160008121A (en) |
-
2015
- 2015-11-25 KR KR1020150165755A patent/KR20160008121A/en not_active Application Discontinuation
Non-Patent Citations (1)
| Title |
|---|
| Exp Dermatol. 20, 595-599, 2011 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101809266B1 (en) | Cosmetic composition containing propolis complex extracts | |
| KR102088728B1 (en) | Cosmetic Composition for Improving Skin Elasticity and Winkles Comprising Plant Complex Extracts as Active Ingredient | |
| JP2017214349A (en) | Cosmetic and Oral Composition | |
| JP2006219432A (en) | Composition having rough skin-preventing activity, cosmetic and beverage | |
| KR101759650B1 (en) | Composition comprising Ocimene or as active ingredients for anti-wrinkle, skin moisturizing, improving skin elasticity, exfoliating, inhibiting erythema or improving skin photo-aging | |
| KR20190088286A (en) | Composition for improving skin beauty comprising extract of fermented soybean fermented with Aspergillus cristatus strain | |
| KR102063686B1 (en) | Skin external composition containing extract of soybean root | |
| KR102544792B1 (en) | Composition Comprising Complex Extract of seaweeds Fermented by Lactobacillus Brevis with Anti-Wrinkling and Elasticity, Antioxidant, and Skin Hydration Property as Active Ingredient | |
| KR101787319B1 (en) | Composition comprising Cinchonine or as active ingredients for anti-wrinkle, skin moisturizing, improving skin elasticity, exfoliating, inhibiting erythema or improving skin photo-aging | |
| US20170196797A1 (en) | Composition containing glycine gracilis oil | |
| KR101777992B1 (en) | Composition comprising Jasmone or as active ingredients for anti-wrinkle, skin moisturizing, improving skin elasticity, exfoliating, inhibiting erythema or improving skin photo-aging | |
| KR20210155989A (en) | Composition Comprising Lactobacillus sakei, Culture Fluid, or Culture Fluid Extract thereof with Anti-Wrinkling and Elasticity, Skin Cell Regeneration, and Skin Barrier Property as Active Ingredient | |
| JP2001316275A (en) | Collagen production promoter, estrogen-like agent, collagenase inhibitor, skin cosmetic, food and drink | |
| KR101777544B1 (en) | Composition comprising Ionol or as active ingredients for anti-wrinkle, skin moisturizing, improving skin elasticity, exfoliating, inhibiting erythema or improving skin photo-aging | |
| KR102221137B1 (en) | A lycoris uydoensis extract comprising anti-wrinkle, anti-inflammatory, anti-oxidation activity, and composition comprising the same, and use thereof | |
| KR102290291B1 (en) | Composition for improving moisturizing skin containing fermented blueberry and black rice extracts | |
| KR102331119B1 (en) | Composition for preventing skin anti-aging comprising fermented black rice extract and fermented peanut sprout extract | |
| KR102337346B1 (en) | Cosmetic composition containing extract of Pinus rigida Mill. for antioxidative or anti-aging | |
| KR101446295B1 (en) | Composition for anti-aging containing sargassum yezoense extract | |
| KR102106440B1 (en) | Composition for improving skin condition comprising blueberry and black rice extract fermented lactic acid bacteria | |
| KR102014961B1 (en) | Composition for anti oxidation containing extract of soybean pod | |
| KR20160008121A (en) | Composition containing amorpha fruticosa extract | |
| KR101958105B1 (en) | Composition comprising Guaiyl acetate or as active ingredients for anti-wrinkle, skin moisturizing, improving skin elasticity, exfoliating, inhibiting erythema or improving skin photo-aging | |
| KR101956666B1 (en) | Composition for improving wrinkle comprising Aneilema keisak Hand.-Mazz. extract and use thereof | |
| KR101719708B1 (en) | Composition for reducing skin wrinkle and for promoting recovery of iskin injury comprising extracts of Orostachys japonicus and Saururus chinensis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E90F | Notification of reason for final refusal | ||
| E601 | Decision to refuse application |